Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

1 ML palivizumab 100 MG/ML Injection [Synagis]

Known as: PALIVIZUMAB 100 mg in 1 mL INTRAMUSCULAR INJECTION, SOLUTION [Synagis], Synagis 100 MG in 1 ML Injection, Synagis 100 MG per 1 ML Injection 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Introduction Un lien entre les infections respiratoires par le virus respiratoire syncytial (VRS) et la primocolonisation precoce… Expand
2013
2013
gastric cancer. Its acquisition is related with poor socioeconomic conditions while the relationship of nutrition and Hp is still… Expand
Review
2012
Review
2012
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a… Expand
2012
2012
Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab utilization and respiratory syncytial virus… Expand
Review
2011
Review
2011
BACKGROUND Respiratory syncytial virus (RSV) is a seasonal infectious disease, with epidemics occurring annually from October to… Expand
  • table 1
  • table 2
  • figure 1
  • table 4
  • figure 2
2004
2004
Le palivizumab (Synagis®) a recu une autorisation d'emploi en France pour la prophylaxie des infections a VRS chez les… Expand
2003
2003
  • SYNAGIS® PALIVIZUMAB
  • 2003
  • Corpus ID: 15935399
DESCRIPTION: Synagis® (palivizumab) is a humanized monoclonal antibody (IgG1κ ) produced by recombinant DNA technology, directed… Expand
Highly Cited
1998
Highly Cited
1998
Background.Respiratory syncytial virus (RSV) is the leading cause of lower respiratory disease in infants and children. MEDI-493… Expand